Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.54 |
| ▸ | CHRNG | P07510 | 1/20 | 0.54 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | CHRND | Q07001 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29589199 | 0.89 | SMN1; SMN2 (0.56) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL19520432 | 0.87 | PARP1 (0.60) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL29923066 | 0.82 | PARP1 (0.59) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL585998 | 0.82 | PARP1 (0.59) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1305879 | 0.81 | SLC6A2 (0.57) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL18068936 | 0.81 | SLC6A2 (0.57) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL15007483 | 0.81 | SLC6A2 (0.57) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL29588379 | 0.81 | SLC6A2 (0.50) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL28567525 | 0.80 | CHRNA1 (0.55) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL8823334 | 0.80 | KMT2A (0.55) | SMN1; SMN2ATMKMT2AHPGDKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921839-B2 | Synthesis of N,N-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem | RANBAXY LABORATORIES LIMITED (IN) | 2005-07-26 | — | — | US | claimed |
| US-20040054230-A1 | Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem | RANBAXY LABORATORIES LIMITED (IN) | 2004-03-18 | — | — | US | claimed |
| EP-1370515-A2 | SYNTHESIS OF N,N-DIMETHYL-3-(4-METHYL) BENZOYL PROPIONAMIDE, A KEY INTERMEDIATE OF ZOLPIDEM | RANBAXY LABORATORIES, LTD. (IN) | 2003-12-17 | — | — | EP | claimed |
| WO-2002018303-A2 | SYNTHESIS OF N,N-DIMETHYL-3-(4-METHYL) BENZOYL PROPIONAMIDE, A KEY INTERMEDIATE OF ZOLPIDEM | RANBAXY LABORATORIES LIMITED (IN) | 2002-03-07 | — | — | WO | claimed |
| US-6921839-B2 | Synthesis of N,N-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem | RANBAXY LABORATORIES LIMITED (IN) | 2005-07-26 | — | — | US | disclosed |
| US-6921839-B2 | Synthesis of N,N-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem | RANBAXY LABORATORIES LIMITED (IN) | 2005-07-26 | — | — | US | disclosed |
| US-20040054230-A1 | Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem | RANBAXY LABORATORIES LIMITED (IN) | 2004-03-18 | — | — | US | disclosed |
| EP-1370515-A2 | SYNTHESIS OF N,N-DIMETHYL-3-(4-METHYL) BENZOYL PROPIONAMIDE, A KEY INTERMEDIATE OF ZOLPIDEM | RANBAXY LABORATORIES, LTD. (IN) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002018303-A2 | SYNTHESIS OF N,N-DIMETHYL-3-(4-METHYL) BENZOYL PROPIONAMIDE, A KEY INTERMEDIATE OF ZOLPIDEM | RANBAXY LABORATORIES LIMITED (IN) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054230-A1 | Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem | GABRA4, GABRA3, GABRA6 | SLC6A2 550/4885SLC6A3 173/4885CHRNA1 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.